Last reviewed · How we verify

Bricanyl/Iprovent — Competitive Intelligence Brief

Bricanyl/Iprovent (Bricanyl/Iprovent) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 adrenergic agonist (Bricanyl); Anticholinergic bronchodilator (Iprovent). Area: Respiratory/Pulmonology.

phase 3 Beta-2 adrenergic agonist (Bricanyl); Anticholinergic bronchodilator (Iprovent) Beta-2 adrenergic receptor (Bricanyl); Muscarinic acetylcholine receptor (Iprovent) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Bricanyl/Iprovent (Bricanyl/Iprovent) — University of Monastir. Bricanyl (terbutaline) is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bricanyl/Iprovent TARGET Bricanyl/Iprovent University of Monastir phase 3 Beta-2 adrenergic agonist (Bricanyl); Anticholinergic bronchodilator (Iprovent) Beta-2 adrenergic receptor (Bricanyl); Muscarinic acetylcholine receptor (Iprovent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-2 adrenergic agonist (Bricanyl); Anticholinergic bronchodilator (Iprovent) class)

  1. University of Monastir · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bricanyl/Iprovent — Competitive Intelligence Brief. https://druglandscape.com/ci/bricanyl-iprovent. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: